A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT ID: NCT03989414
Last Updated: 2024-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
424 participants
INTERVENTIONAL
2019-09-30
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A: CC-92480 with bortezomib and dexamethasone
CC-92480
Specified dose on specified days
Bortezomib
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Cohort C: CC-92480 with carfilzomib and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Carfilzomib
Specified dose on specified days
Cohort H: CC-92480 with elotuzumab and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Elotuzumab
Specified dose on specified days
Cohort I: CC-92480 with isatuximab and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Isatuximab
Specified dose on specified days
Cohort D: CC-92480 with bortezomib and dexamethasone
CC-92480
Specified dose on specified days
Bortezomib
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Cohort F: CC-92480 with carfilzomib and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Carfilzomib
Specified dose on specified days
Cohort J: CC-92480 with elotuzumab and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Elotuzumab
Specified dose on specified days
Cohort K: CC-92480 with isatuximab and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Isatuximab
Specified dose on specified days
Cohort G: CC-92480 with bortezomib and dexamethasone
CC-92480
Specified dose on specified days
Bortezomib
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Subcohort B1: CC-92480 with daratumumab and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Daratumumab
Specified dose on specified days
Subcohort B2: CC-92480 with daratumumab and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Daratumumab
Specified dose on specified days
Subcohort B3: CC-92480 with daratumumab and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Daratumumab
Specified dose on specified days
Subcohort E1: CC-92480 with daratumumab and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Daratumumab
Specified dose on specified days
Subcohort E2: CC-92480 with daratumumab and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Daratumumab
Specified dose on specified days
Subcohort E3: CC-92480 with daratumumab and dexamethasone
CC-92480
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Daratumumab
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CC-92480
Specified dose on specified days
Bortezomib
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Daratumumab
Specified dose on specified days
Carfilzomib
Specified dose on specified days
Elotuzumab
Specified dose on specified days
Isatuximab
Specified dose on specified days
Carfilzomib
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:
* Documented diagnosis of multiple myeloma (MM) and measurable disease
* Documented disease progression during or after their last antimyeloma regimen
* Achieved a response (minimal response \[MR\] or better) to at least 1 prior treatment regimen
Exclusion Criteria
* Known central nervous system (CNS) involvement with myeloma
* Received immunosuppressive medication within the last 14 days of initiating study treatment
* Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 119
Denver, Colorado, United States
Local Institution - 104
Tampa, Florida, United States
Local Institution - 108
Atlanta, Georgia, United States
Local Institution - 112
Chicago, Illinois, United States
Local Institution - 107
Chicago, Illinois, United States
Local Institution - 117
Boston, Massachusetts, United States
Local Institution - 101
Boston, Massachusetts, United States
Local Institution - 118
Boston, Massachusetts, United States
Local Institution - 113
Detroit, Michigan, United States
Local Institution - 106
Rochester, Minnesota, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Local Institution - 110
Winston-Salem, North Carolina, United States
Local Institution - 115
Columbus, Ohio, United States
Local Institution - 114
Nashville, Tennessee, United States
Local Institution - 116
Houston, Texas, United States
Swedish Cancer Institute
Seattle, Washington, United States
Local Institution - 201
Calgary, Alberta, Canada
Local Institution - 205
Edmonton, Alberta, Canada
Local Institution - 204
Halifax, Nova Scotia, Canada
Local Institution - 203
Toronto, Ontario, Canada
Local Institution - 202
Montreal, Quebec, Canada
Local Institution - 802
Brno, , Czechia
Local Institution - 801
Ostrava-Poruba, , Czechia
Local Institution - 803
Prague, , Czechia
Local Institution - 902
Odense, , Denmark
Local Institution - 903
Vejle, , Denmark
Local Institution - 703
Lille, , France
Local Institution - 705
Marseille, , France
Local Institution - 704
Nantes, , France
Local Institution - 701
Toulouse, , France
Local Institution - 702
Tours, , France
Local Institution - 604
Freiburg im Breisgau, , Germany
Local Institution - 605
Hamburg, , Germany
Local Institution - 601
Heidelberg, , Germany
Local Institution - 602
München, , Germany
Local Institution - 603
Würzburg, , Germany
Local Institution - 301
Athens, , Greece
Local Institution - 404
Brescia, , Italy
Local Institution - 401
Milan, , Italy
Local Institution - 403
Reggio Emilia, , Italy
Local Institution - 402
Torino, , Italy
Local Institution - 504
Badalona, , Spain
Local Institution - 508
Madrid, , Spain
Local Institution - 501
Madrid, , Spain
Local Institution - 506
Málaga, , Spain
Local Institution - 505
Pamplona, , Spain
Local Institution - 502
Salamanca, , Spain
Local Institution - 503
Santander, , Spain
Local Institution - 507
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1233-5619
Identifier Type: OTHER
Identifier Source: secondary_id
2023-505219-19
Identifier Type: REGISTRY
Identifier Source: secondary_id
CC-92480-MM-002
Identifier Type: -
Identifier Source: org_study_id